TFA Therapeutics, Inc. (RAJAF) stock
RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on May 15, 2026Score 7/30
$9.18+0.00 (0.00%)
Close on Oct 16, 2026Market cap –P/E –Yield –
TFA Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
TFA Therapeutics's ebitda for the twelve months ending Dec 31, 2023 was $284.59K. For fiscal 2023 it was $284.59K.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $284.59K | – |
| FY2022 | Dec 31, 2022 | -$390.63K | -1408.6% |
| FY2021 | Dec 31, 2021 | $29.85K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $176.17K | – |
See a number that looks wrong?